Logo image of EXPR

EXPRESS INC (EXPR) Stock Fundamental Analysis

NYSE:EXPR - New York Stock Exchange, Inc. - US30219E2028 - Common Stock - Currency: USD

2.29  +0.06 (+2.69%)

Fundamental Rating

2

EXPR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 121 industry peers in the Specialty Retail industry. EXPR has a medium profitability rating, but doesn't score so well on its financial health evaluation. EXPR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

EXPR had negative earnings in the past year.
EXPR had a negative operating cash flow in the past year.
In multiple years EXPR reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: EXPR reported negative operating cash flow in multiple years.
EXPR Yearly Net Income VS EBIT VS OCF VS FCFEXPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M -400M

1.2 Ratios

The Return On Assets of EXPR (12.19%) is better than 88.28% of its industry peers.
The Return On Equity of EXPR (120.91%) is better than 97.66% of its industry peers.
Industry RankSector Rank
ROA 12.19%
ROE 120.91%
ROIC N/A
ROA(3y)-2.64%
ROA(5y)-3.25%
ROE(3y)-1730.52%
ROE(5y)-1046.08%
ROIC(3y)N/A
ROIC(5y)N/A
EXPR Yearly ROA, ROE, ROICEXPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

EXPR has a better Profit Margin (10.01%) than 92.97% of its industry peers.
In the last couple of years the Profit Margin of EXPR has grown nicely.
The Gross Margin of EXPR (22.40%) is worse than 76.56% of its industry peers.
In the last couple of years the Gross Margin of EXPR has remained more or less at the same level.
Industry RankSector Rank
OM N/A
PM (TTM) 10.01%
GM 22.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y78.26%
GM growth 3Y1.31%
GM growth 5Y-0.5%
EXPR Yearly Profit, Operating, Gross MarginsEXPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20

More info and screens

1

2. Health

2.1 Basic Checks

EXPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EXPR has been increased compared to 1 year ago.
The number of shares outstanding for EXPR has been reduced compared to 5 years ago.
Compared to 1 year ago, EXPR has an improved debt to assets ratio.
EXPR Yearly Shares OutstandingEXPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
EXPR Yearly Total Debt VS Total AssetsEXPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

EXPR has an Altman-Z score of 0.97. This is a bad value and indicates that EXPR is not financially healthy and even has some risk of bankruptcy.
EXPR has a Altman-Z score of 0.97. This is in the lower half of the industry: EXPR underperforms 69.53% of its industry peers.
EXPR has a Debt/Equity ratio of 1.83. This is a high value indicating a heavy dependency on external financing.
EXPR has a Debt to Equity ratio of 1.83. This is in the lower half of the industry: EXPR underperforms 67.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Altman-Z 0.97
ROIC/WACCN/A
WACC15.82%
EXPR Yearly LT Debt VS Equity VS FCFEXPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.98 indicates that EXPR may have some problems paying its short term obligations.
EXPR has a worse Current ratio (0.98) than 86.72% of its industry peers.
EXPR has a Quick Ratio of 0.98. This is a bad value and indicates that EXPR is not financially healthy enough and could expect problems in meeting its short term obligations.
EXPR has a Quick ratio of 0.19. This is amonst the worse of the industry: EXPR underperforms 85.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.19
EXPR Yearly Current Assets VS Current LiabilitesEXPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

EXPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -521.75%.
Measured over the past years, EXPR shows a very strong growth in Earnings Per Share. The EPS has been growing by 76.94% on average per year.
EXPR shows a decrease in Revenue. In the last year, the revenue decreased by -8.11%.
The Revenue has been decreasing by -2.89% on average over the past years.
EPS 1Y (TTM)-521.75%
EPS 3YN/A
EPS 5Y76.94%
EPS Q2Q%29.1%
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y-2.63%
Revenue growth 5Y-2.89%
Sales Q2Q%4.6%

3.2 Future

EXPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.01% yearly.
The Revenue is expected to grow by 2.32% on average over the next years.
EPS Next Y-135.77%
EPS Next 2Y14.55%
EPS Next 3Y16.01%
EPS Next 5YN/A
Revenue Next Year-1.98%
Revenue Next 2Y2.16%
Revenue Next 3Y2.32%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EXPR Yearly Revenue VS EstimatesEXPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B
EXPR Yearly EPS VS EstimatesEXPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EXPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EXPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXPR Price Earnings VS Forward Price EarningsEXPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EXPR Per share dataEXPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200 300 400

4.3 Compensation for Growth

EXPR's earnings are expected to grow with 16.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.55%
EPS Next 3Y16.01%

More info and screens

0

5. Dividend

5.1 Amount

EXPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXPRESS INC

NYSE:EXPR (3/6/2024, 8:04:00 PM)

2.29

+0.06 (+2.69%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)11-30 2023-11-30/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners197.99%
Ins Owner Change0%
Market Cap8.59M
Analysts82.86
Price Target20.4 (790.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.5%
Min EPS beat(2)3.19%
Max EPS beat(2)19.81%
EPS beat(4)3
Avg EPS beat(4)1.52%
Min EPS beat(4)-31.14%
Max EPS beat(4)19.81%
EPS beat(8)6
Avg EPS beat(8)57.46%
EPS beat(12)10
Avg EPS beat(12)110.69%
EPS beat(16)11
Avg EPS beat(16)59.58%
Revenue beat(2)0
Avg Revenue beat(2)-4.35%
Min Revenue beat(2)-5.54%
Max Revenue beat(2)-3.17%
Revenue beat(4)0
Avg Revenue beat(4)-4.56%
Min Revenue beat(4)-6.05%
Max Revenue beat(4)-3.17%
Revenue beat(8)1
Avg Revenue beat(8)-3.63%
Revenue beat(12)3
Avg Revenue beat(12)-2.74%
Revenue beat(16)3
Avg Revenue beat(16)-5.37%
PT rev (1m)21.21%
PT rev (3m)21.21%
EPS NQ rev (1m)-34.22%
EPS NQ rev (3m)-703.11%
EPS NY rev (1m)-7.14%
EPS NY rev (3m)-55.01%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)-4.96%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-3.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-49.74
EYN/A
EPS(NY)-15.54
Fwd EYN/A
FCF(TTM)-63.72
FCFYN/A
OCF(TTM)-51.35
OCFYN/A
SpS476.52
BVpS39.45
TBVpS39.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.19%
ROE 120.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 10.01%
GM 22.4%
FCFM N/A
ROA(3y)-2.64%
ROA(5y)-3.25%
ROE(3y)-1730.52%
ROE(5y)-1046.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y78.26%
GM growth 3Y1.31%
GM growth 5Y-0.5%
F-Score4
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.49%
Cap/Sales 2.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.19
Altman-Z 0.97
F-Score4
WACC15.82%
ROIC/WACCN/A
Cap/Depr(3y)50.21%
Cap/Depr(5y)50.38%
Cap/Sales(3y)1.93%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-521.75%
EPS 3YN/A
EPS 5Y76.94%
EPS Q2Q%29.1%
EPS Next Y-135.77%
EPS Next 2Y14.55%
EPS Next 3Y16.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y-2.63%
Revenue growth 5Y-2.89%
Sales Q2Q%4.6%
Revenue Next Year-1.98%
Revenue Next 2Y2.16%
Revenue Next 3Y2.32%
Revenue Next 5YN/A
EBIT growth 1Y-924.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.87%
EBIT Next 3Y36.9%
EBIT Next 5YN/A
FCF growth 1Y-1482.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3156.62%
OCF growth 3YN/A
OCF growth 5YN/A